Hypofractionated Radiotherapy for Refractory or Relapsed Aggressive B-cell Lymphoma in the Rituximab Era

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Jan 13

PMID 38218811

Authors

Cheng Huang

Tian-Lan Tang

Yan-Yan Qiu

Yu-Ping Lin

Si-Lin Chen

Rui-Zhi Zhao

Gui-Qing Shi

Si-Qin Liao

Jin-Hua Chen

Hai-Ying Fu

Jian-Zhi Liu

Ben-Hua Xu

Ting-Bo Liu

Yong Yang

Affiliations

Soon will be listed here.

Abstract

Background: Radiotherapy (RT) is an effective and available local treatment for patients with refractory or relapsed (R/R) aggressive B-cell lymphomas. However, the value of hypofractionated RT in this setting has not been confirmed.

Methods: We retrospectively analyzed patients with R/R aggressive B-cell lymphoma who received hypofractionated RT between January 2020 and August 2022 at a single institution. The objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and acute side effects were analyzed.

Results: A total of 30 patients were included. The median dose for residual disease was 36 Gy, at a dose per fraction of 2.3-5 Gy. After RT, the ORR and complete response (CR) rates were 90% and 80%, respectively. With a median follow-up of 10 months (range, 2-27 months), 10 patients (33.3%) experienced disease progression and three died. The 1-year OS and PFS rates for all patients were 81.8% and 66.3%, respectively. The majority (8/10) of post-RT progressions involved out-of-field relapses. Patients with relapsed diseases, no response to systemic therapy, multiple lesions at the time of RT, and no response to RT were associated with out-of-field relapses. PFS was associated with response to RT (P = 0.001) and numbers of residual sites (P < 0.001). No serious non-hematological adverse effects (≥ grade 3) associated with RT were reported.

Conclusion: These data suggest that hypofractionated RT was effective and tolerable for patients with R/R aggressive B-cell lymphoma, especially for those that exhibited localized residual disease.

References

Miller T, Dahlberg S, Cassady J, Adelstein D, Spier C, Grogan T . Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998; 339(1):21-6. DOI: 10.1056/NEJM199807023390104. View

Freeman C, Savage K, Villa D, Scott D, Srour L, Gerrie A . Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2020; 137(7):929-938. DOI: 10.1182/blood.2020005846. View

Susanibar-Adaniya S, Barta S . 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021; 96(5):617-629. PMC: 8172085. DOI: 10.1002/ajh.26151. View

Hoppe B, Moskowitz C, Zhang Z, Maragulia J, Rice R, Reiner A . The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2009; 43(12):941-8. DOI: 10.1038/bmt.2008.408. View

Bento L, Gutierrez A, Novelli S, Montoro J, Pinana J, Lopez-Corral L . Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplant. 2021; 56(8):1919-1928. DOI: 10.1038/s41409-021-01264-3. View

Sim A, Jain M, Figura N, Chavez J, Shah B, Khimani F . Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019; 105(5):1012-1021. PMC: 6872916. DOI: 10.1016/j.ijrobp.2019.05.065. View

Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C . Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014; 32(11):1112-8. DOI: 10.1200/JCO.2013.51.4505. View

Ng A, Shbib Dabaja B, Hoppe R, Illidge T, Yahalom J . Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era. J Clin Oncol. 2016; 34(13):1443-7. DOI: 10.1200/JCO.2015.64.9418. View

Robinson S, Boumendil A, Finel H, Blaise D, Poire X, Nicolas-Virelizier E . Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2015; 51(3):365-71. DOI: 10.1038/bmt.2015.286. View

10.

Dabaja B, Vanderplas A, Crosby-Thompson A, Abel G, Czuczman M, Friedberg J . Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2014; 121(7):1032-9. PMC: 5531172. DOI: 10.1002/cncr.29113. View

11.

Rossi C, Andre M, Dupuis J, Morschhauser F, Joly B, Lazarovici J . High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline. Haematologica. 2022; 107(12):2897-2904. PMC: 9713544. DOI: 10.3324/haematol.2021.280004. View

12.

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

13.

Dhakal S, Bates J, Casulo C, Friedberg J, Becker M, Liesveld J . Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. Int J Radiat Oncol Biol Phys. 2016; 96(2):372-378. DOI: 10.1016/j.ijrobp.2016.05.021. View

14.

Lue J, OConnor O . A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. Lancet Haematol. 2020; 7(11):e838-e850. DOI: 10.1016/S2352-3026(20)30222-2. View

15.

Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z . Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 86(3):569-77. DOI: 10.1016/j.ijrobp.2013.02.007. View

16.

Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, OConnor O . Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2020; 137(19):2634-2645. PMC: 8138546. DOI: 10.1182/blood.2020007512. View

17.

Ballonoff A, Rusthoven K, Schwer A, McCammon R, Kavanagh B, Bassetti M . Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2008; 72(5):1465-71. DOI: 10.1016/j.ijrobp.2008.02.068. View

18.

Mei M, Lee H, Palmer J, Chen R, Tsai N, Chen L . Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022; 139(25):3605-3616. PMC: 9227101. DOI: 10.1182/blood.2022015423. View

19.

Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova Y . The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2018; . DOI: 10.1111/ejh.13080. View

20.

Nastoupil L, Jain M, Feng L, Spiegel J, Ghobadi A, Lin Y . Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38(27):3119-3128. PMC: 7499611. DOI: 10.1200/JCO.19.02104. View